Table 1.
Association between CD155 expression and clinical pathological features.
| N | Percentage of tumor cells with CD155 overexpression | p | |
|---|---|---|---|
| Age, correlation coefficient† | 126 | -0.026 | 0.774 |
| Histological grade† | |||
| I | 13 | 5% (17%) | 0.049 |
| II | 79 | 32% (45%) | |
| III | 26 | 42% (48%) | |
| ER status‡ | |||
| Negative | 31 | 56% (47%) | <0.001 |
| Positive | 90 | 21% (39%) | |
| PR status‡ | |||
| Negative | 41 | 35% (46%) | 0.307 |
| Positive | 80 | 27% (43%) | |
| HER2 overexpression‡ | |||
| Negative | 63 | 26% (42%) | 0.223 |
| Positive | 21 | 40% (47%) | |
| TNM stage† | |||
| I | 30 | 23% (41%) | 0.58 |
| II | 67 | 36% (46%) | |
| III | 18 | 21% (38%) | |
| IV | 6 | 50% (55%) | |
†Spearman correlation test. ‡Mann–Whitney U test.